Hugel, Inc. (KOSDAQ:145020)

Market Cap	2.65T -22.3%
Revenue (ttm)	479.57B +18.9%
Net Income	157.98B +8.4%
EPS	14,398.49 +12.2%
Shares Out	10.80M
PE Ratio	17.02
Forward PE	20.00
Dividend	n/a
Ex-Dividend Date	n/a

Volume	26,572
Open	249,500
Previous Close	252,000
Day's Range	242,500 - 250,500
52-Week Range	208,500 - 342,000
Beta	0.56
Analysts	Strong Buy
Price Target	369,312.50 (+50.74%)
Earnings Date	Nov 6, 2026

About Hugel

Hugel, Inc. develops and manufactures biopharmaceuticals in South Korea and internationally. The company offers Botulinum Toxin, a white injectable dry powder in a transparent glass vial for use in the treatment of positive essential eyelid convulsion in adults over 18 years of age; improvement of severe lasso wrinkles associated with corrugator muscles and/or procerus muscle activities in adults aged between 18 and 65; treatment of upper limb stroke; and treatment of dynamic equinus foot deformity in children with cerebral palsy over 2 years o...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2001
• Employees: 604
• Stock Exchange: KOSDAQ
• Ticker Symbol: 145020

Financial Performance

In 2025, Hugel's revenue was 425.11 billion, an increase of 13.96% compared to the previous year's 373.05 billion. Earnings were 140.87 billion, an increase of 3.72%.

Analyst Summary

According to 16 analysts, the average rating for 145020 stock is "Strong Buy." The 12-month stock price target is ₩369,313, which is an increase of 50.74% from the latest price.

Price Target

₩369,313

(50.74% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 1, 2026

Data Sources Report a data error